<DOC>
	<DOCNO>NCT02227706</DOCNO>
	<brief_summary>To evaluate safety effectiveness EVICEL® Fibrin Sealant ( Human ) adjunct achieve haemostasis surgery paediatric patient .</brief_summary>
	<brief_title>The Paediatric EVICEL® Soft Tissue Parenchymal Organ Bleeding Study</brief_title>
	<detailed_description>This prospective , randomize , control , clinical study compare EVICEL® SURGICEL® , adjunct haemostasis conventional method control bleed ineffective impractical surgery paediatric patient . At least 40 qualified paediatric subject appropriate mild moderate Target Bleeding Site ( TBS ) randomize 1:1 allocation ratio either EVICEL® SURGICEL® . Haemostasis assess 4 , 7 10 minute randomization . Enrolment stagger age ( require European Medicines Agency ( EMA ) Paediatric Committee ) . The first group enrol include least 36 subject age ≥1 year &lt; 18 year age . When enrolment first group complete ; enrolment subsequent group commence include least 4 subject birth ( include neonate ≤37 week gestation ) &lt; 1 year age . Subjects follow post-operatively hospital discharge 30 day ( ±14 day ) post-surgery .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Fibrin Tissue Adhesive</mesh_term>
	<criteria>Paediatric subject birth &lt; 18 year age , require nonemergent laparoscopic open ( peritoneum pleura ) abdominal , retroperitoneal , pelvic thoracic ( noncardiac ) surgical procedure . ) The first 36 subject enrolled subject ≥1 year &lt; 18 year age . ii ) The next 4 subject enrolled subject birth &lt; 1years age . The subject and/or subject 's parent legal guardian must willing give permission subject participate trial , provide write informed consent subject . If possible , assent must obtain paediatric subject possess intellectual emotional ability comprehend concept involve trial . If paediatric subject able provide assent ( due age , maturity and/or inability intellectually and/or emotionally comprehend trial ) , parent/legal guardian 's write informed consent subject acceptable subject include study ; Presence appropriate mild moderate bleeding soft tissue parenchymal organ Target Bleeding Site identify intraoperatively surgeon ; Subjects know intolerance blood product one component study product unwilling receive blood product ; Female subject , childbearing age ( i.e . adolescent ) , pregnant nursing ; Subject currently participate , study plan participate investigational device drug trial without prior approval Sponsor ; Subjects know , current alcohol and/or drug abuser ; Subjects admit trauma surgery ; Subjects pre intraoperative finding identify surgeon may preclude conduct study procedure ; Subjects Target Bleeding Site actively infect field ( Class III Contaminated Class IV Dirty Infected ) Anastomotic bleeding site consider randomization .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Fibrin Sealant</keyword>
	<keyword>Hemostatics</keyword>
	<keyword>Coagulants</keyword>
</DOC>